While blood-based tests are readily available for various conditions, including
cardiovascular diseases, type 2 diabetes, and common cancers, Alzheimer's disease (AD) …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because
clinical symptoms are strongly correlated with tau aggregates, drug development and …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Proteomics can shed light on the dynamic and multifaceted alterations in neurodegenerative
disorders like Alzheimer's disease (AD). Combining radioligands measuring β-amyloid (Aβ) …

Recent expansion of proteomic coverage opens unparalleled avenues to unveil new
biomarkers of Alzheimer's disease (AD). Among 6,361 cerebrospinal fluid (CSF) proteins …

Objective A clock relating amyloid positron emission tomography (PET) to time was used to
estimate the timing of biomarker changes in sporadic Alzheimer disease (AD). Methods …

Abstract Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising
biomarker for reliable detection of Alzheimer's disease pathology. Various p-tau217 assays …